## Abstract Local anesthetics procaine and tetracaine have been specifically‐deuterated in two and three positions, respectively, for use in deuterium nuclear magnetic resonance experiments. The experimental procedure is either new or an adaptation of early synthetic methods.
Synthesis of side chain specifically deuterated (−)-Δ9-tetrahydrocannabinols
✍ Scribed by Spyros P. Nikas; Ganesh A. Thakur; Alexandros Makriyannis
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- French
- Weight
- 111 KB
- Volume
- 45
- Category
- Article
- ISSN
- 0022-2135
- DOI
- 10.1002/jlcr.626
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
(−)‐Δ^9^‐Tetrahydrocannabinols specifically deuterated at the n‐pentyl side chain were prepared using the corresponding resorcinols as key intermediates. To obtain the deuterated resorcinols we developed conditions under which no deuterium scrambling or loss was observed. The methodology allows for the preparative scale synthesis of deuterated resorcinols and corresponding (−)‐Δ^9^‐tetrahydrocannabinols. Copyright © 2002 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract Site specific deuterated primaquines were prepared. The attempts to prepare these by deuterolysis of bromoprimaquines were unsuccessful because the required bromoprimaquines could not be produced satisfactorily by alkylation of the various bromo‐6‐ methoxy‐8‐aminoquinolines. Instead pri
## Abstract Two site specifically deuterated primaquines were prepared. 4′,4′‐Dideutero primaquine **3** was obtained from the corresponding dideutero alcohol which was prepared by the low temperature reduction of the ester compound **4** with lithium aluminium deuteride. 1′‐Deutero primaquine r wa
## Abstract BG9928, a high affinity adenosine A~1~ antagonist, is currently in Phase II clinical trials for the treatment of congestive heart failure. A deuterium‐labeled version of the molecule was synthesized and used as a standard for __in vivo__ pharmacokinetic and __in vitro__ metabolism studi
## Abstract Syntheses of 1‐(isopropylamino)‐3‐(1‐naphthyloxy)‐2‐propanol‐1,1,2,3,3‐d~5~ (**1**), 3‐(1‐naphthyloxy)‐1,2‐propanediol‐1,1,2,3,3‐d5 (**2**) and 1‐(isopropylamino)‐3‐(4‐hydroxy‐1‐naphthyloxy)‐2‐propanol‐1,1,2,3,3‐d5 (**3**) from epichlorohydrin‐d5 are described. Treatment of epichlorohyd